Indexed in / abstracted by
Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]
A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.
BIOLOGICAL MOLECULES IN CLINICAL STROKE TRIALS
Stroke remains a leading cause of disability and mortality all over the world despite the efforts made towards improving treatment. Most of the clinical studies have not shown signifi cant benefi cial effects in the evaluation of various molecules for their neuroprotection and neurorecovery promoting properties. The new concept of multimodal, pleiotropic drugs has opened new perspectives in this fi eld. This review focuses on clinical stroke studies with biologically active molecules such as erythropoietin, granulocyte-colony stimulating factor and Cerebrolysin.
Keywords: neuroprotection, neurorecovery, multimodal, pleiotropic drugs
Full text | PDF